SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Ligand (LGND) Breakout!
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
32384 154 0 LGND
Emcee:  Henry Niman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
311346:54PM Ligand Pharms (LGND) 7.96 -1.12: -- Update -- Company also sees operatingSemiBull-8/13/2002
31133Ligand Reports Financial Results for Second Quarter 2002: Total Revenues IncreasSemiBull-8/13/2002
31132Based on last Q's issuance of report, we should get this Q's report afteArthur Radley-8/1/2002
31131Appears investors are finally realizing that LGND was over sold in the recent doArthur Radley-7/30/2002
31130Not anecdotes, aboutoxycontin.com Oxycontin and their makers regulation is now Cacaito-7/26/2002
31129Gregory - thanks for the perspective .... John McCarthyJohn McCarthy-7/24/2002
31128deletedscaram(o)uche-7/24/2002
31127We may be going a little astray here but I would make a few points. Bearing in Gregory Rasp-7/24/2002
31126It goes for 10X "cost" in some areas........ <i>Q: How Does Oxyscaram(o)uche-7/23/2002
31125Huh? It's a widely abused prescription drug. There's no anecdote to myscaram(o)uche-7/23/2002
31124What Richard said, plus Oxy can be snorted to give an opiate rush, not somethingArchie Meeties-7/23/2002
31123you forget that many patients don't pay for their chronic opiates - it'sArchie Meeties-7/23/2002
31122This discussion is HIGHLY anecdotal and I am giving you credit for having a littSPSEIFERT-7/23/2002
31121Not 100X cost, but 100X *their* cost, the copay. Sure. Physician to patient viscaram(o)uche-7/23/2002
31120That is the first good reason, other than first mover, listed here. 100X... reaHarold Engstrom-7/23/2002
31119>> Why will patients prefer ocycontin hands down? << Some of them wscaram(o)uche-7/23/2002
31118Why will patients prefer ocycontin hands down?Harold Engstrom-7/23/2002
31117Harold, The answer depends on if you're in academic medicine or not. AcadeArchie Meeties-7/23/2002
31116Ye Olde Vendor Lunche. In manufacturing circles the pizza is accompanied by gruHarold Engstrom-7/23/2002
31115Well I can only speak for myself and my immediate associates but we tend to relyGregory Rasp-7/22/2002
31114GR, thanks again for your perspective. A question and a comment: Question: do Harold Engstrom-7/22/2002
31113Ligand program with Wyeth should get a boost after HRT debacle. 2 Phase III in pCacaito-7/22/2002
31112Harold I am not aware of any compelling advantages but no detail person has beeGregory Rasp-7/18/2002
31111Are you saying there is nothing compelling about Avinza? Or familiar? My underHarold Engstrom-7/17/2002
31110I have seen the literature but have not been tempted. Unless a drug is familiarGregory Rasp-7/17/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News